{
    "clinical_study": {
        "@rank": "102559", 
        "arm_group": [
            {
                "arm_group_label": "XGEVA inception cohort"
            }, 
            {
                "arm_group_label": "Zoledronic acid inception cohort"
            }, 
            {
                "arm_group_label": "XGEVA-switch cohort"
            }
        ], 
        "brief_summary": {
            "textblock": "A non-interventional study to assess incident rates of Osteonecrosis of the Jaw and\n      Infections leading to hospitalization in Cancer patients treated with XGEVA\u2122 in Sweden,\n      Denmark and Norway."
        }, 
        "brief_title": "Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA\u2122 or Zoledronic Acid", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "ONJ", 
            "Infection"
        ], 
        "condition_browse": {
            "mesh_term": "Osteonecrosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2265 18 years old\n\n          -  diagnosed with cancer\n\n          -  subsequent to cancer diagnosis, initiating cancer-related antiresorptive treatment\n             during the treatment cohort identification period with XGEVA or zoledronic acid or\n             switching to XGEVA from cancer-related treatment with oral or IV bisphosphonates of\n             less than 2 years duration (\u2264 24 IV infusions or \u2264 24 monthly oral prescriptions)\n\n        Exclusion Criteria:\n\n          -  history of radiation treatment for head and neck cancer before a subject's potential\n             index date\n\n          -  hypercalcemia of malignancy as the indication for treatment with an anti-resorptive\n             agent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Cancer patients treated with antiresorptive therapies"
            }
        }, 
        "enrollment": {
            "#text": "3600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967160", 
            "org_study_id": "20101363"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Zoledronic acid", 
                "Diphosphonates"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "lastchanged_date": "November 25, 2013", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "number_of_groups": "3", 
        "official_title": "A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA\u2122 or Zoledronic Acid in Sweden, Denmark, and Norway", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Sweden: The National Board of Health and Welfare", 
                "Norway: Regional Ethics Commitee", 
                "Denmark: National Board of Health"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "1. Incidence proportions of medically confirmed osteonecrosis of the jaw (ONJ) in XGEVA and zoledronic acid inception cohorts", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "2. Incidence proportions of infections leading to hospitalization in XGEVA and zoledronic acid inception cohorts", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967160"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "1. Incidence proportions of medically confirmed ONJ in the cohort switching from IV bisphosphonate to XGEVA", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "2. Incidence proportions of medically confirmed ONJ in the cohort switching from IV bisphosphonate to XGEVA stratified by number of prior cancer-related bisphosphonate treatments", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "3. Number of bisphosphonate treatments prior to initiation of XGEVA treatment for patients in the cohort switching from IV bisphosphonate to XGEVA", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "collaborator": {
                "agency": "Aarhus University Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}